TC
BPMC

TwinBeech Capital’s Blueprint Medicines BPMC Stock Holding History

TwinBeech Capital’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-32,157
Closed -$2.97M – 566
2023
Q4 		$2.97M Buy
+32,157
New +$2.08M 0.05% 346
2023
Q2 		– Sell
-4,849
Closed -$218K – 616
2023
Q1 		$218K Buy
+4,849
New +$218K ﹤0.01% 560
2022
Q4 		– Sell
-53,549
Closed -$3.53M – 708
2022
Q3 		$3.53M Buy
53,549
+43,535
+435% +$2.8M 0.09% 247
2022
Q2 		$506K Buy
+10,014
New +$587K 0.02% 416
2020
Q2 		– Sell
-8,524
Closed -$498K – 365
2020
Q1 		$498K Buy
+8,524
New +$549K 0.2% 153

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TwinBeech Capital's BPMC Position: Q1 2024 in Review

TwinBeech Capital sold out of Blueprint Medicines (BPMC) in Q1 2024, closing a stake of 32,157 shares — an estimated $2.97M sold.

TwinBeech Capital first reported a position in BPMC in Q1 2020 and held it in 5 quarters. The position peaked at $3.53M in Q3 2022. 283 funds tracked by Wall St. Rank hold BPMC as of Q1 2024.

  • TwinBeech Capital reported no remaining Blueprint Medicines position as of Q1 2024 after selling out during the quarter.
  • TwinBeech Capital sold 32,157 Blueprint Medicines shares in Q1 2024, an estimated $2.97M.
  • TwinBeech Capital first reported a position in Blueprint Medicines in Q1 2020 and held it in 5 quarters.
  • TwinBeech Capital's Blueprint Medicines position peaked at $3.53M in Q3 2022.
  • 283 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2024.

Based on TwinBeech Capital's 13F filing for Q1 2024, filed 15 May 2024.